...mouse models of lung cancer. Syntrix Pharmaceuticals has SX-682 in Phase I testing for melanoma. Dompe Farmaceutici...

...FDA approved Oxervate cenegermin from Dompe Farmaceutici S.p.A. (Milan, Italy) to treat neurotrophic keratitis, a rare eye...
...has breakthrough therapy, Orphan Drug status and Fast Track designation from FDA for the indication. Dompe Farmaceutici...
...S.p.A., Milan, Italy Product: Oxervate cenegermin Business: Ophthalmic Sandi Wong Recombinant human nerve growth factor (rhNGF), cenegermin (oxervate) Dompe Farmaceutici...

...FDA approved Oxervate cenegermin from Dompe Farmaceutici S.p.A. (Milan, Italy) to treat neurotrophic keratitis, a rare eye...
...Fast Track designation from FDA for the indication. Sandi Wong Recombinant human nerve growth factor (rhNGF), cenegermin (oxervate) Dompe Farmaceutici...

...least five companies have small molecule inhibitors of MDM2 in preclinical-Phase I testing for cancer. Dompe Farmaceutici...
...Mass. Buck Institute for Research on Aging, Novato, Calif. CanBas Co. Ltd. (Tokyo:4575), Numazu, Japan Dompe Farmaceutici...

...The European Commission approved an MAA from Dompe Farmaceutici S.p.A. (Milan, Italy) for Oxervate cenegermin to treat...
...Dompe Farmaceutici S.p.A. , Milan, Italy Product: Oxervate cenegermin Business: Ophthalmic Chris Lieu cenegermin Oxervate Recombinant human nerve growth factor (rhNGF) Dompe Farmaceutici...

...EMA’s CHMP recommended approval of an MAA from Dompe Farmaceutici S.p.A. (Milan, Italy) for Oxervate cenegermin to...
...and has Orphan Drug designation for the indication. EMA reviewed the MAA under accelerated assessment. Dompe Farmaceutici...
...cenegermin (Recombinant human nerve growth factor , rhNGF) Business: Ophthalmic Julian Zhu Recombinant human nerve growth factor (rhNGF) Dompe Farmaceutici cenegermin Oxervate...

...no treatment. Next steps include investigating the mechanisms that regulate CXCL1 expression in cancer cells. Dompe Farmaceutici...